An uncharacterized serine/threonine-protein kinase SBK3 that is encoded in the genome of human. [PRO:DAN]
EC 2.7.11.1;
SH3-binding domain kinase family member 3;
Sugen kinase 110
Timeframe | Studies on this Protein(%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
---|---|---|---|---|---|
imatinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
staurosporine | Homo sapiens (human) | Kd | 0.0250 | 1 | 1 |
gefitinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
lestaurtinib | Homo sapiens (human) | Kd | 0.1200 | 2 | 2 |
vatalanib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
ruboxistaurin | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
canertinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
birb 796 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
sb 203580 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
enzastaurin | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
erlotinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
lapatinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
sorafenib | Homo sapiens (human) | Kd | 10.0000 | 2 | 2 |
pd 173955 | Homo sapiens (human) | Kd | 1.1000 | 1 | 1 |
s 1033 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
bms 387032 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
tandutinib | Homo sapiens (human) | Kd | 10.0000 | 2 | 2 |
vx-745 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
dasatinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
zd 6474 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
alvocidib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
bosutinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
su 11248 | Homo sapiens (human) | Kd | 1.9000 | 2 | 2 |
vx680 | Homo sapiens (human) | Kd | 0.5300 | 1 | 1 |
axitinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
pd 184352 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
bms345541 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
midostaurin | Homo sapiens (human) | Kd | 10.0000 | 2 | 2 |
ki 20227 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
pi103 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
hki 272 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
tofacitinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
cediranib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
masitinib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
pazopanib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
azd 6244 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
su 14813 | Homo sapiens (human) | Kd | 5.0000 | 1 | 1 |
bibw 2992 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
tg100-115 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
pha 665752 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | Homo sapiens (human) | Kd | 0.1900 | 1 | 1 |
brivanib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
at 7519 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
bi 2536 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
nvp-ast487 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
kw 2449 | Homo sapiens (human) | Kd | 0.2300 | 1 | 1 |
abt 869 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
gw 2580 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
crizotinib | Homo sapiens (human) | Kd | 0.2400 | 1 | 1 |
chir-265 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
motesanib | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
mln8054 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
GDC-0879 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
gsk 461364 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
azd 1152-hqpa | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
nvp-tae684 | Homo sapiens (human) | Kd | 0.0540 | 1 | 1 |
fedratinib | Homo sapiens (human) | Kd | 2.9000 | 1 | 1 |
gsk690693 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
gdc 0941 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
plx 4720 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
sgx 523 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
quizartinib | Homo sapiens (human) | Kd | 10.0000 | 2 | 2 |
incb-018424 | Homo sapiens (human) | Kd | 5.8000 | 1 | 1 |
gsk 1838705a | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
gsk 1363089 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
chir 258 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
nintedanib | Homo sapiens (human) | Kd | 2.0000 | 1 | 1 |
pp242 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
This protein enables 4 target(s):
Target | Category | Definition |
---|---|---|
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
ATP binding | molecular function | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. [ISBN:0198506732] |
protein serine kinase activity | molecular function | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate. [RHEA:17989] |
protein serine/threonine kinase activity | molecular function | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate. [GOC:bf, MetaCyc:PROTEIN-KINASE-RXN, PMID:2956925] |